



PANCREASURE TEST FOR EARLY DETECTION OF PANCREATIC CANCER AVAILABLE TO HIGH-RISK PATIENTS—FIRST TESTS ALREADY ORDERED

LUND, Sweden – Immunovia (publ.), the pancreatic cancer diagnostics company, today launched the PancreaSure test for early detection of pancreatic cancer in high-risk individuals. The test is now being offered at several leading pancreatic cancer high-risk surveillance programs in the U.S, and the first orders have already been placed.

“People at risk for pancreatic cancer often ask if there is a blood test to detect the disease. PancreaSure is a big step in that direction. It’s exciting to be able to offer high-risk individuals a convenient blood test that can be used in conjunction with imaging that may be able detect pancreatic cancer,” said Erkut Borazanci, M.D., Medical Director of Honor Health Research Institute’s Oncology Research Division.

The PancreaSure test is now available at seven top U.S. pancreatic cancer surveillance programs, including:

- Hackensack Meridian
- Honor Health Research Institute (Arizona)
- Northwestern University Feinberg School of Medicine
- University of Colorado
- University of Pennsylvania

“Pancreatic cancer is so lethal because it’s usually diagnosed too late,” said Rosario Ligresti, M.D., Chief of Gastroenterology at Hackensack Medical Center. “We need more ways to detect pancreatic cancer early, especially in people at high risk. The PancreaSure test has proven to accurately detect stage 1 and 2 disease, making it an important addition to our toolkit.”

Dr. Borazanci, Dr. Ligresti and clinicians leading the programs above have already ordered the PancreaSure test for patients.

The launch of the PancreaSure test has also been welcomed by patient advocacy organizations.

Sue Friedman, Founder and Executive Director of Facing Our Risk of Cancer Empowered (FORCE) said, “As a leading organization for people with inherited cancer risk, FORCE applauds the research that led to the development of the PancreaSure test. The FORCE

community includes people with a very high risk for pancreatic cancer, a deadly cancer with few options for early detection. Our community is desperate for less invasive ways to help screen for pancreatic cancer. On a professional level as a patient advocate, and on a personal level as a BRCA2 mutation carrier, I feel that this is a step in the right direction."

PancreaSure Test Pricing

PancreaSure is currently a patient-pay test. The list price is \$995; patients can lower the cost to \$750 by paying promptly. Financial assistance is available to lower the cost of the PancreaSure test for those with financial need. The cost of the test for those who qualify is \$0, \$100 or \$200 based on need. Immunovia expects to begin billing insurance in 2026.

PancreaSure Testing Process

Physicians order the PancreaSure test through Immunovia's online portal. The high-risk individual's blood is drawn and then sent to the Immunovia lab in North Carolina, USA. After processing, PancreaSure test results are shared with the physician in the online portal.

About the PancreaSure test

PancreaSure is a blood test that seeks to detect early-stage pancreatic cancer in high-risk individuals. In the CLARITI study of 1,066 samples from patients with pancreatic cancer and high-risk controls, the PancreaSure test demonstrated sensitivity of 78%, meaning it detected nearly 4 out of 5 early stage cancers. The test demonstrated specificity of 94%, meaning that the test was negative for 94% of samples with no cancer. Early detection dramatically improves treatment outcomes, and PancreaSure can give physicians and patients the opportunity to act when intervention is most effective.

For further information, please contact

Jeff Borcharding, CEO

jeff.borcharding@immunovia.com

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit www.immunovia.com.